Table 2.

Patient demographics and clinico-pathological features at baseline and follow-up

Patient	Age	Baseline Gleason	TNM Stage	PSA baseline (ng/mL)	PSA at 1 month (ng/mL)	PSA at 6 months (ng/mL)	No. positive sextants	Post-PDT Gleason
1	68	3 + 3	T2A	3.8	2.1	3.4	2	3 + 4
2	72	3 + 4	T1C	6.8	1.4	1.8	2	4 + 4
3	63	3 + 3	T2A	3.8	8.0	3.7	4	3 + 4
4	70	3 + 3	T2B	3.0	1.2	2.0	2	3 + 4
5	62	3 + 4	T2C	5.2	1.0	1.8	2	3 + 3
6	72	3 + 3	T2B	2.5	2.8	1.7	2	3 + 3
7	76	3 + 4	T2C	6.4	1.7	2.2	2	3 + 4
8	74	3 + 3	T2A	2.1	1.0	0.6	Negative	Negative
9	83	3 + 4	T1A	15.5	1.7	3.8	3	3 + 4
10	71	3 + 3	T2B	4.8	4.6	4.5	Negative	Negative
11	74	3 + 4	T2A	5.5	3.9	8.0	4	4 + 4
12	70	3 + 4	T2A	9.6	0.4	0.8	1	3 + 4
13	75	3 + 3	T1C	1.9	0.3	0.1	Negative	Negative
14	75	3 + 4	T2B	4.5	0.1	0.0	Negative	Negative
15	75	3 + 4	T1C	13.4	6.2	17.90	Negative	Negative

PSA: prostate-specific antigen; PDT: photodynamic therapy.